DexCom, Inc. (Nasdaq:DXCM), the global leader in glucose biosensing, is ushering in the next era of transformative, customer-driven innovation under the leadership of President and CEO Jake Leach, who ...
Lingo is Abbott’s over-the-counter continuous glucose monitor (CGM) for nondiabetic people. Withings users will also be able ...
DexCom overview and recent share performance DexCom (DXCM) has drawn fresh attention as investors reassess its continuous glucose monitoring business and recent share performance, with the stock last ...
(COLORADO SPRINGS) — FOX21 News has learned alternative ways people are getting around the shortage of the medical device called the Dexcom, a glucose monitor for diabetes. Some diabetics are now ...
DexCom, Inc.'s growth is impressive but limited by its niche market, with my projected ceiling being ~$7.5bn in peak annual revenues. Despite positive Q4 2024 results, DexCom's stock is fairly valued, ...
Brown Advisory, an investment management company, released its “Brown Advisory Mid-Cap Growth Strategy” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. The strategy ...
Bank of America Securities analyst Travis Steed maintained a Buy rating on Dexcom today and set a price target of $100.00. According to TipRanks, Steed is a 4-star analyst with an average return of 7.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback